The Generic (Gx) segment, in particular, has been a standout performer for Amneal. Analysts project that this segment experienced about 17% growth in the third quarter of 2024, with the Injectable ...

Also Read: Generic Drug Maker Amneal Pharmaceuticals Is Positioned To Growth Well Ahead Of Peers, Analyst Upgrades Stock It clocked a net loss of $31 million compared to a net loss of $99 million ...

Wrapping up Q4 earnings, we look at the numbers and key takeaways for the generic pharmaceuticals stocks, including Amneal (NASDAQ:AMRX) and its peers. The generic pharmaceutical industry operates ...

Amneal Pharmaceuticals, Inc., a global biopharmaceutical company, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty ...

Amneal Pharmaceuticals (AMRX) is experiencing significant financial growth by focusing on making generic drugs more affordable and accessible—a ...

In October 2023, Teva Pharmaceuticals filed a patent infringement lawsuit against Amneal Pharmaceuticals alleging that their generic version of Teva’s ProAir® HFA inhaler infringed upon the ...

BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”) today announced its results for the fourth quarter and full year ended December ...

In August 2024, the FDA approved Amneal’s IPX203 for Parkinson’s disease as Crexont (Carbidopa and Levodopa) extended-release capsules. The generic drug was launched in September. J.P. Morgan analyst ...

The generic drug segment, a key driver of Amneal’s business, has shown particularly impressive growth. Analysts project a 17% growth for the generic segment in the third quarter of 2024 ...

Amneal Pharmaceuticals (NYSE:NASDAQ:AMRX), a commercial-stage biopharmaceutical company with a market capitalization of $2.74 billion, has been making significant strides in the pharmaceutical ...